These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
81 related articles for article (PubMed ID: 7865439)
1. Taxol (paclitaxel): a novel advance in chemotherapy. Ann Oncol; 1994; 5 Suppl 6():1-62. PubMed ID: 7865439 [No Abstract] [Full Text] [Related]
2. [Paclitaxel (Taxol) in chemotherapy of head and neck cancer--just another proposal or breakthrough?]. Górecka KM; Golusiński W; Gawecki W; Szyfter K Otolaryngol Pol; 2001; 55(5):471-6. PubMed ID: 11868318 [TBL] [Abstract][Full Text] [Related]
3. [Taxol and related diterpenoids of Taxus sp.: important acquisitions in the treatment of cancer]. Vanhaelen MH J Pharm Belg; 1992; 47(5):417-24. PubMed ID: 1362218 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, tissue distribution and anti-tumour efficacy of paclitaxel delivered by polyvinylpyrrolidone solid dispersion. Liu X; Sun J; Chen X; Wang S; Scott H; Zhang X; Zhang Q J Pharm Pharmacol; 2012 Jun; 64(6):775-82. PubMed ID: 22571255 [TBL] [Abstract][Full Text] [Related]
5. Workshop on Taxol and Taxus. Introduction. Broder S; Karp JE J Natl Cancer Inst Monogr; 1993; (15):1-4. PubMed ID: 7912514 [No Abstract] [Full Text] [Related]
6. Paclitaxel (Taxol): a review of its antitumor activity in clinical studies Minireview. Hájek R; Vorlicek J; Slavik M Neoplasma; 1996; 43(3):141-54. PubMed ID: 8841500 [TBL] [Abstract][Full Text] [Related]
7. Clinical development of Taxol. Arbuck SG; Christian MC; Fisherman JS; Cazenave LA; Sarosy G; Suffness M; Adams J; Canetta R; Cole KE; Friedman MA J Natl Cancer Inst Monogr; 1993; (15):11-24. PubMed ID: 7912517 [TBL] [Abstract][Full Text] [Related]
9. Pharmacogenomics of importance for paclitaxel chemotherapy. Green H Pharmacogenomics; 2008 Jun; 9(6):671-4. PubMed ID: 18518845 [TBL] [Abstract][Full Text] [Related]
10. [Current issues in the chemotherapy of malignant tumors. Taxol (paclitaxel), Taxoter]. Gorbunova VA; Garin AM; Tiuliandin SA; Orel NF; Roshchin EM; Voĭnarevich OA Vopr Onkol; 1994; 40(7-12):259-66. PubMed ID: 7610618 [No Abstract] [Full Text] [Related]
12. Growth inhibition of a human ovarian tumor by a novel paclitaxel derivative in SCID mice. Ahmad I; Masters GR; Schupsky JJ; Nguyen J; Ali S; Janoff AS; Mayhew E Oncol Res; 1999; 11(6):273-80. PubMed ID: 10691029 [TBL] [Abstract][Full Text] [Related]
13. Taxol inhibits growth of mesothelioma xenografts. Lee JM; Bruckner HW; Szrajer L; Brenne U; Schindelheim G; Andreotti PE Anticancer Res; 1995; 15(3):693-6. PubMed ID: 7645945 [TBL] [Abstract][Full Text] [Related]
14. Treatment with paclitaxel alone rather than combination with paclitaxel and cisplatin may be selective for cisplatin-resistant ovarian carcinoma. Yamamoto K; Kikuchi Y; Kudoh K; Hirata J; Kita T; Nagata I Jpn J Clin Oncol; 2000 Oct; 30(10):446-9. PubMed ID: 11185891 [TBL] [Abstract][Full Text] [Related]
16. Taxol and cisplatin inhibit proliferation of T47D human breast cancer cells. Kodali S; Burkley M; Nag K; Taylor RC; Moudgil VK Biochem Biophys Res Commun; 1994 Aug; 202(3):1413-9. PubMed ID: 7914723 [TBL] [Abstract][Full Text] [Related]
17. Nab-paclitaxel in the treatment of metastatic breast cancer: a comprehensive review. Montero AJ; Adams B; Diaz-Montero CM; Glück S Expert Rev Clin Pharmacol; 2011 May; 4(3):329-34. PubMed ID: 22114779 [TBL] [Abstract][Full Text] [Related]
18. A BTB/POZ gene, NAC-1, a tumor recurrence-associated gene, as a potential target for Taxol resistance in ovarian cancer. Ishibashi M; Nakayama K; Yeasmin S; Katagiri A; Iida K; Nakayama N; Fukumoto M; Miyazaki K Clin Cancer Res; 2008 May; 14(10):3149-55. PubMed ID: 18483383 [TBL] [Abstract][Full Text] [Related]
19. In vivo toxicity and bioavailability of Taxol and a paclitaxel/beta-cyclodextrin formulation in a rat model during HIPEC. Bouquet W; Ceelen W; Adriaens E; Almeida A; Quinten T; De Vos F; Pattyn P; Peeters M; Remon JP; Vervaet C Ann Surg Oncol; 2010 Sep; 17(9):2510-7. PubMed ID: 20339948 [TBL] [Abstract][Full Text] [Related]
20. [Taxol (paclitaxel) as second-line therapy in breast and ovarian cancer]. Borovik R; Steiner M; Atad J; Sneiderman B; Rosenberg T; Palti S Harefuah; 1998 Apr; 134(8):605-8, 671. PubMed ID: 10911422 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]